Fig. 1. NF-κB and I-κB proteins. RHD: rel homology domain, LZ: leucine zipper. The arrows point to the C-terminal residues of p50 and p52 (following processing of p105 and p100, respectively).
Invited Review
NF-κB and Therapeutic ApproachChang Hoon LEE, and Soo Youl KIM* Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea (Received July 14, 2009; Accepted July 23, 2009) Abstract -Since NF-κB has been identified as a transcription factor associated with immune cell activation, groups of researchers have dedicated to reveal detailed mechanisms of nuclear factor of κB (NF-κB) in inflammatory signaling for decades. The various molecular components of NF-κB transcription factor pathway have been being evaluated as important therapeutic targets due to their roles in diverse human diseases including inflammation, cystic fibrosis, sepsis, rheumatoid arthritis, cancer, atherosclerosis, ischemic injury, myocardial infarction, osteoporosis, transplantation rejection, and neurodegeneration. With regards to new drugs directly or indirectly modulating the NF-κB pathway, FDA recently approved a proteasome inhibitor bortezomib for the treatment of multiple myeloma. Many pharmaceutical companies have been trying to develop new drugs to inhibit various kinases in the NF-κB signaling pathway for many therapeutic applications. However, a gene knock-out study for IKKβ in the NF-κB pathway has given rise to controversies associated with efficacy as therapeutics. Mice lacking hepatocyte IKKβ accelerated cancer instead of preventing progress of cancer. However, it is clear that pharmacological inhibition of IKKβ appears to be beneficial to reduce HCC. This article will update issues of the NF-κB pathway and inhibitors regulating this pathway.Keywords: NF-κB, IKKβ, Inflammation, Cancer, Transglutaminase 2, NF-κB inhibitor
NF-κB AND I-κB PROTEINSThere are five mammalian reticuloendotheliosis family/nuclear factor of κB (REL/NF-κB) proteins that belong to two groups: the first one that does not require proteolytic processing and the second one that requires proteolytic processing (Fig. 1). The first group includes RELA (p65), c-REL and RELB. The second group includes NF-κB1 (p105) and NF-κB2 (p100). p105 and p100 are processed to produce the mature p50 and p52 proteins, respectively. These two groups form dimers -the most commonly detected NF-κB dimer is p65-p50. Due to the presence of a strong transcriptional activation domain, p65 is responsible for most of NF-κB transcriptional activity. NF-κB dimers are regulated by interactions with inhibitor of κB (I-κB) proteins. NF-κB binding with I-κB causes their cytoplasmic retention unless I-κB is degraded in proteasome. RELB associates with p100 in B-cells. The p100-RELB dimers exist exclusively in cytoplasm. Proteolytic processing of p100 results in the release of p52-RELB dimers, which translocate to the nucleus. RELB can have both activating